Sahajanand Medical Technologies Ltd.

Sahajanand Medical Technologies Ltd. At SMT, we are revolutionizing healthcare through innovation and clinical excellence.

With a presence in 80+ countries and a diverse global workforce, SMT is driving innovation to meet the needs of healthcare professionals. We are a leading developer and manufacturer of minimally invasive coronary stent systems, with one of the broadest product portfolios in the industry. We at SMT believe in continuous innovation and up-gradation of our portfolio in order to cater to your healthcare needs. Our commitment is to advance patient care by introducing state of the art medical devices which will enable us to save precious lives.

Sahajanand Medical Technologies Ltd. (SMT) is pleased to announce that we have been honoured with the EY Pharma Award fo...
01/12/2025

Sahajanand Medical Technologies Ltd. (SMT) is pleased to announce that we have been honoured with the EY Pharma Award for Best Medical Device Company in the category of Export Promotion at the 12th edition of the India Pharma Awards, held on 25th November 2025 at the India Expo Centre, Greater Noida, Delhi NCR. his recognition stands as a testament to India’s strengthening presence on the global MedTech map and SMT’s commitment to shaping that journey. The award was received by Dr Rajiv Chhibber,VP External Affairs and his team on behalf of SMT.

Over the years, SMT has built a global footprint across Europe, APAC, Middle East and the Latin American region. This milestone reinforces the credibility of SMT as a global partner in advancing cardiovascular care.

The award is also an acknowledgment of our R&D, robust innovation ecosystem, and quality culture. As an Indian conglomerate rooted in advancing scientific technology, SMT has consistently focused on developing best-in-class medical technologies while ensuring an optimal experience for healthcare providers and patients alike. This recognition motivates us to continue pushing boundaries and delivering next-generation solutions to global markets.

At SMT, Excellence, Care, Innovation, and Agility are more than values, they are the foundation of our identity. This accolade reaffirms our commitment to being “Pledged to Save Millions”, a mission that inspires every member of the SMT family. We extend our gratitude to the Jury, E&Y team, our global partners, clinicians, customers, and teams whose constant support has made this achievement possible. The journey ahead is promising, and together, we will continue elevating patient care across the world.

We are pleased to invite the interventional cardiology community to two focused scientific sessions by SMT at GIS 2025, ...
26/11/2025

We are pleased to invite the interventional cardiology community to two focused scientific sessions by SMT at GIS 2025, where leading clinicians will share evidence and real-world insights in PCI and TAVR.

Session 1A

Topic: Improving Outcomes in PCI: The Clinical Evidence Behind Supraflex Cruz

Speaker: Dr. Samih Lawand, MD, FRCPC, FACC

Affiliation: Consultant Interventional Cardiologist; Head of Cardiology, Dallah Hospital, Riyadh KSA

Date: 28 November 2025

Time: 14:30 – 14:45

Venue: Hall B, Intercontinental Dubai Festival City

Session 1B

Topic: Hydra Valve: Case-Based Learning & Updated Evidence

Speaker: Dr. Waleed Al Harbi

Affiliation: Interventional Cardiology Consultant, King Khaled University Hospital

Date: 28 November 2025

Time: 14:45 – 15:00

Venue: Hall B, Intercontinental Dubai Festival City

SMT continues to support evidence-based innovation and meaningful scientific exchange.We look forward to meeting the global community at GIS 2025.

Sahajanand Medical Technologies is pleased to announce its participation in the GIS Annual Conference, taking place in D...
25/11/2025

Sahajanand Medical Technologies is pleased to announce its participation in the GIS Annual Conference, taking place in Dubai, UAE from 27–29 November 2025.

We invite all attendees to visit our booth to explore our latest product innovations and newly generated clinical evidence. We look forward to engaging with you at GIS 2025.

Happy World Children’s Day!Today, we celebrate the joy, resilience, and limitless potential of every child.At SMT, our m...
20/11/2025

Happy World Children’s Day!

Today, we celebrate the joy, resilience, and limitless potential of every child.

At SMT, our mission with the Cocoon range of occluders is simple yet powerful — to help ensure that every child born with a congenital heart defect has the chance to grow up with a healthy, strong heartbeat.

Grateful to all the physicians and partners who make this possible every day.

Every child deserves a healthy start… and a healthy heart.

We’re delighted to share the success of our participation at PCR London Valves 2025!A key highlight of the event was the...
19/11/2025

We’re delighted to share the success of our participation at PCR London Valves 2025!

A key highlight of the event was the presentation of Hydra CE 5-year outcomes by Dr. Vilhelmas Bajoras, showcasing Hydra’s sustained safety, durability, and hemodynamic performance in long-term TAVR outcomes.

We extend our heartfelt thanks to all speakers, collaborators, and attendees who contributed to making this session truly impactful. Your engagement and insights continue to drive meaningful progress in structural heart innovation.

A special note of appreciation to everyone who visited our SMT booth, and to the event organizers and scientific committee for their exceptional efforts in creating a world-class platform for sharing cutting-edge clinical evidence.

Together, we continue to advance minimally invasive cardiac care and redefine the future of transcatheter valve therapy.

The     2025 congress is the perfect opportunity to explore the latest developments in TAVR.Don’t miss the session highl...
16/11/2025

The 2025 congress is the perfect opportunity to explore the latest developments in TAVR.

Don’t miss the session highlighting the 5-year outcomes of Hydra, along with key insights from clinical experts on real-world experience and valve performance.

Date: Tuesday, 18th November 2025
Time: 08:30 AM (GMT)
Venue: Room B

We look forward to welcoming you to important discussions on advancing TAVR therapy with Hydra.

Join Sahajanand Medical Technologies Ltd. at PCR London Valves 2025 to learn more about Hydra, our self-expanding TAVR s...
12/11/2025

Join Sahajanand Medical Technologies Ltd. at PCR London Valves 2025 to learn more about Hydra, our self-expanding TAVR system.

Booth: A17
Venue: ExCeL, London
Dates: 16th – 18th November 2025

Meet our global team, explore the latest clinical insights and real-world experience with Hydra, and engage in conversations shaping the future of Structural Heart therapy.

Don’t miss the chance to see Hydra in action at PCR LondonValves 2025.

Sahajanand Medical Technologies is pleased to announce its recent successful participation in the “16th CIAT Annual Scie...
11/11/2025

Sahajanand Medical Technologies is pleased to announce its recent successful participation in the “16th CIAT Annual Scientific Conference 2025” in Bangkok, Thailand

The event was full of engaging sessions and latest treatment modalities in the field of cardiology.

The event also gave SMT the opportunity to highlight its latest robust clinical data with Supraflex Cruz stent and 6F KBT for Pipit NC PTCA ballons

We would like to thank every participant for engaging with the SMT team and helping in making the event a successful one.

We endeavour to assure that SMT continues to invest in clinical trials , in alignment with its mission of “Pledged to save millions”.

We also thank our Business Partner Alliance Pharma Co. Ltd. for their commitment & service throughout our journey together.

Sahajanand Medical Technologies is proud to announce their successful maiden Hydra THV deployment in The Dedinje Institu...
03/11/2025

Sahajanand Medical Technologies is proud to announce their successful maiden Hydra THV deployment in The Dedinje Institute of Cardiovascular Diseases, in Belgrade, Serbia!

At the outset, we specially thank Dr. Mihajlo Farkic for performing the case with his sheer dexterity & experience, assisted by Dr. Matija Furtula. The case was proctored by none other than Dr. Alfonso Ielasi, sharing his valuable experience in the therapy field.

We also thank Dragan Topić & Dr. Mladen Tasić for their presence.

The Cruz Senior Study, the largest prospective PCI study in patients aged 80+ (n = 1993), shows that PCI with the Supraf...
29/10/2025

The Cruz Senior Study, the largest prospective PCI study in patients aged 80+ (n = 1993), shows that PCI with the Supraflex Cruz stent is safe and effective in very elderly and frail patients. At 12 months, Target Lesion Revascularization (TLR) was just 2.4% and Target Vessel MI was 2.2%, reflecting a robust safety profile. Patients experienced meaningful improvement in symptoms and daily functioning, with clear gains in quality of life. As emphasized by Prof. Dr. David Leistner, these findings confirm that even the oldest patients can benefit safely and significantly from PCI when treated with Supraflex Cruz.

The Multivessel TALENT Trial, a major multinational evaluation chaired by Prof. Patrick W. Serruys (Ireland), across 54 ...
28/10/2025

The Multivessel TALENT Trial, a major multinational evaluation chaired by Prof. Patrick W. Serruys (Ireland), across 54 sites in Europe with 1,550 patients, compared Supraflex Cruz with Synergy in three-vessel coronary artery disease. The primary endpoint, Patient-Oriented Composite Endpoint (POCE) at 12 months, confirmed non-inferiority of Supraflex Cruz. When excluding periprocedural myocardial infarction, Supraflex Cruz showed a numerically lower POCE rate, and in patients with SYNTAX score >33, POCE was notably lower with Supraflex Cruz (14.6% vs 22.8%, log-rank p = 0.167). These outcomes highlight the strong and reliable performance of Supraflex Cruz in the setting of complex three-vessel disease, expanding its role in advanced PCI scenarios. Presented under the leadership of Prof. Patrick W. Serruys.

The TUXEDO-II Trial, a pivotal, large-scale comparison of Supraflex Cruz and Xience in 1,800 diabetic patients with mult...
28/10/2025

The TUXEDO-II Trial, a pivotal, large-scale comparison of Supraflex Cruz and Xience in 1,800 diabetic patients with multivessel disease across 66 sites in India, demonstrated that Supraflex Cruz achieved clinical outcomes comparable to Xience. The primary endpoint, Target Lesion Failure (TLF) at 1 year, confirmed non-inferiority, while Supraflex Cruz also showed a 23% numerically lower rate of Target Lesion Revascularization (TLR) (log-rank p = 0.44). These findings reaffirm that Supraflex Cruz performs strongly in one of the most challenging high-risk patient subsets, validating the reliability of biodegradable polymer DES technology and offering interventional cardiologists a proven and confident alternative for diabetic multivessel revascularization. Presented under the leadership of Chairperson Dr. Upendra Kaul (India) and Co-Chair Dr. Sripal Bangalore (USA).

Address

Sahajanand Estate, Wakhariawadi, Nr. Dabholi Char Rasta, Ved Road
Surat
395004

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm
Saturday 8:30am - 5pm

Telephone

+912616112800

Alerts

Be the first to know and let us send you an email when Sahajanand Medical Technologies Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Sahajanand Medical Technologies Ltd.:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram